STOCKscreener 
 .  i  n  f  o 
                
Novartis AG News
 Login   Help  
 
    
 Home 
 About   News 
 Indices 2019 
 Market News 
 Company News 
 Performance 
 Momentum 
 All Time Highs 
 Trading Systems 
 The STOCK BLOCK 
 Links 
 
 Impressum 
 
 
company details RSS feed
 
 Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors 2011-09-05 
 Novartis International BioCamp spotlights how diversity spurs innovation across the company and inspires future science leaders 2011-08-29 
 FDA requests additional clinical data on Novartis drug ACZ885 for the treatment of gouty arthritis 2011-08-29 
 Novartis drug Afinitor® recommended by CHMP for EU approval to treat patients with advanced pancreatic neuroendocrine tumors 2011-07-22 
 Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19 
 Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers for 2011-2012 influenza season 2011-07-15 
 Phase III trial of Novartis drug Afinitor® met primary endpoint of reducing SEGA tumor size in patients with tuberous sclerosis 2011-07-08 
 Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need 2011-07-05 
 Novartis receives FDA approval for Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary disease 2011-07-01 
 Novartis receives approval in Japan for Onbrez® Inhalation Capsules, a novel once-daily bronchodilator therapy for patients with COPD 2011-07-01 
 Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD 2011-06-30 
 Novartis drug Votubia® recommended by CHMP for approval in the EU for children and adults with SEGA associated with tuberous sclerosis 2011-06-24 
 FDA panel endorses efficacy but not safety of Novartis drug ACZ885 for gouty arthritis; did not support approval in proposed indication 2011-06-22 
 Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia 2011-06-16 
 Novartis application for expanded Menveo® indication from 2 months of age accepted for review by FDA 2011-06-16 
 Novartis candidate vaccine Bexsero® shows significant potential in providing broad coverage against meningococcal serogroup B infections 2011-06-09 
 Novartis gains European Commission approval for Lucentis® to treat vision loss due to macular edema secondary to RVO 2011-06-06 
 Novartis drug Glivec® shows significant overall survival benefit for patients with GIST after three years of adjuvant treatment vs. one year 2011-06-05 
 Novartis JAK inhibitor INC424 shows significant clinical benefit for myelofibrosis patients in two Phase III studies at ASCO 2011-06-04 
 Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2011-06-01 
 Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid 2011-05-25 
 Alcon wins Patanol® US patent infringement lawsuit against Apotex 2011-05-24 
 Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly 2011-05-19 
 Novartis provides restated consolidated income statement data for 2010 and Q1 2011 following the merger with Alcon; no change to total reported Group data 2011-05-18 
 Novartis studies show Onbrez® Breezhaler® plus tiotropium is more effective than tiotropium alone in treatment of COPD 2011-05-15 
 Novartis drug Votubia® approved as first medication in Switzerland for SEGA, a benign brain tumor associated with tuberous sclerosis 2011-05-11 
 Novartis gains FDA approval for Afinitor® as first new treatment in nearly three decades for patients with advanced pancreatic NET 2011-05-06 
 New analysis representing largest available dataset highlights relative safety of Lucentis® (ranibizumab) compared to unlicensed intravitreal Avastin® (bevacizumab) 2011-05-04 
 Novartis receives EU approval for Rasilamlo®, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2011-04-28 
 Novartis makes strong start for the year 2011-04-19 
 Novartis drug Afinitor® recommended by FDA oncology advisory committee for approval to treat advanced NET of pancreatic origin 2011-04-12 
 Novartis discontinues clinical trial of Tasigna® for investigational use in newly diagnosed patients with unresectable and/or metastatic GIST 2011-04-11 
 Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows 2011-04-11 
 Novartis amends current US FDA application for Afinitor® to seek indication for advanced neuroendocrine tumors of pancreatic origin 2011-04-08 
 Novartis completes merger with Alcon 2011-04-08 
 Novartis shareholders approve merger of Alcon into Novartis 2011-04-08 
 Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis 2011-04-07 
 Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows 2011-03-31 
 FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD 2011-03-23 
 Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China 2011-03-22 
 
Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice.
Impressum